Bioinformatics Test Engineer

Organization
Illumina
Job Location
5200 Illumina Way
San Diego, CA 92122
Job Description

This role is to provide bioinformatics test support for Illumina’s data analysis software. As a bioinformatics test engineer, you will work in a cross functional team to perform verification and validation on Next Generation Sequencing (NGS) analysis. You will also be working with workflow automation/management applications                                                     

The successful candidate must be a fast learner with strong sense of ownership, motivation, and detail orientated.

Responsibilities:

  • Work independently in cross-functional teams to lead the testing effort for bioinformatics data analysis software.
  • Apply knowledge to develop, modify, and execute software test plans and test cases.
  • Develop and execute automation script for data validation.
  • Work with software developers, bioinformatics scientists and domain experts in designing, performing, and improving the verification process.
  • Collaborate with peers to identify opportunities for process improvement. 
Requirements
  • Bachelor or Master Degree (or higher) in Bioinformatics, Computational Science, or related field from an accredited university (or foreign equivalent).
  • Good verbal and written communication and troubleshooting skills.
  • Solid understanding of genetics, NGS technique, human genome analysis familiar with bioinformatics tools and algorithm.
  • Working experience with Linux and Windows OS, experience with scripting (such as bash or Python) and object-oriented programming (such as C#) is a must.
  • Previous working experience involving Bioinformatics software development or testing is preferred.

Familiarity with databases (such as MySQL or PostGreSQL) , Cloud computing (such as Amazon Web Services), and web service is a plus.

About Our Organization

Headquartered in San Diego, California, Illumina (NASDAQ: ILMN), is a leading developer, manufacturer, and marketer of next generation life science tools and integrated systems for large-scale analysis of genetic variation and biological function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With the innovative advances in our sequencing technologies, we are rapidly impacting the clinical market in areas such as reproductive health and oncology. The expanding Illumina oncology portfolio of next- generation sequencing NGS and microarray technologies is revolutionizing cancer genomics research. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

lllumina has experienced phenomenal growth from $10 million in revenues in 2002 to over $1.4 billion in 2013. Forbes named Illumina #1 on the 2009 list of 25 Fastest-Growing Technology Companies in the United States, the second time over a three year period that Forbes ranked Illumina #1 on its list of rapidly growing technology companies. Illumina was also named #1 smartest company in the world as part of MIT’s 2014 Technology Review.  As of August 2014, the company had a $24 billion market capitalization.

The US National Institutes of Health's new plan will bolster support for early- and mid-career investigators.

Steven Hyman writes at Nature News that staff scientists could help research institutions take on ambitious research projects.

The NIH proposes using a Grant Support Index to limit the total amount of grant support any one principal investigator can have.

A survey of UK academics found that women tended to have higher teaching loads than men, according to Nature News.